Navidea Biopharmaceuticals, Inc (NAVB)
-NYSE MKT | Prev Close: | 2.45 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.31 |
|---|
| Beta: | 1.03 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.14 - 4.77 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,398,240 |
|---|
| Market Cap: | 286.04M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.28 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NAVIDEA BIOPHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, FinancEDGAR Online(Thu, May 16)
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awarenessat Motley Fool(Wed, May 15)
- Nordion signs contract manufacturing agreement with Navideatheflyonthewall.com(Wed, May 15)
- Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with NordionBusiness Wire(Wed, May 15)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemeEDGAR Online(Thu, May 9)
- Navidea Biopharmaceuticals, Inc Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Q1 2013 Navidea Biopharmaceuticals Inc Earnings Release - Before Market OpenCCBN(Wed, May 8)
- Navidea Biopharmaceuticals Announces First Quarter 2013 ResultsBusiness Wire(Wed, May 8)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Tue, May 7)
- Companies Developing Targeted Cancer Treatments Seek Higher Profits In 2013at Seeking Alpha(Mon, May 6)
- Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013Business Wire(Fri, May 3)
- Navidea Biopharmaceuticals, Inc - Special Callat Seeking Alpha(Wed, May 1)
- Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek®Business Wire(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 4,281.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.23 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents.
View More